ViferaXS
Biotechnology company developing peptide-based T cell activators for cancer and infectious diseases. Uses immunopeptidome analysis to identify tumor-associated and neoepitopes for rapid design of off-the-shelf therapeutic vaccinations and combines these antigens with adjuvant formulations intended to elicit durable T cell responses. Maintains clinical programs including a Phase II-ready program in chronic lymphocytic leukemia (CLL) and multiple ongoing clinical trials.
Industries
Nr. of Employees
small (1-50)
Products
T cell activator for cancer
Peptide-based therapeutic vaccination approach combining tumor-associated peptides identified from the immunopeptidome with adjuvant formulations to elicit tumor-directed T cell responses; includes clinical programs up to Phase II readiness in CLL.
T cell activator for infectious diseases
Application of the peptide-based T cell activator platform to generate T cell–focused immunotherapies for infectious disease indications.
T cell activator for cancer
Peptide-based therapeutic vaccination approach combining tumor-associated peptides identified from the immunopeptidome with adjuvant formulations to elicit tumor-directed T cell responses; includes clinical programs up to Phase II readiness in CLL.
T cell activator for infectious diseases
Application of the peptide-based T cell activator platform to generate T cell–focused immunotherapies for infectious disease indications.
Services
Immunopeptidome analysis and antigen discovery
Rapid identification of naturally presented tumor-associated peptides to inform off-the-shelf immunotherapy composition and co-development projects.
Immunopeptidome analysis and antigen discovery
Rapid identification of naturally presented tumor-associated peptides to inform off-the-shelf immunotherapy composition and co-development projects.
Expertise Areas
- Immunopeptidomics and neoepitope discovery
- Peptide vaccine and T cell activator development
- Adjuvant formulation for T cell responses
- Translational immunology and clinical development
Key Technologies
- Immunopeptidomics (MHC ligandome analysis)
- Peptide-based T cell activators
- Adjuvant formulations for T cell induction
- Neoepitope identification